Doctors test smart cancer treatment that changes based on patient response
NCT ID NCT07340398
Summary
This study is testing a personalized approach to treating early-stage HER2-positive breast cancer before surgery. All participants start with standard chemotherapy and targeted drugs. Doctors then check how well the tumor is responding. Patients with a good response continue the same treatment, while those with a less-than-ideal response switch to a stronger, investigational drug combination. The goal is to give each person the most effective treatment while avoiding unnecessary side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.